JP2022512944A5 - - Google Patents

Info

Publication number
JP2022512944A5
JP2022512944A5 JP2021524370A JP2021524370A JP2022512944A5 JP 2022512944 A5 JP2022512944 A5 JP 2022512944A5 JP 2021524370 A JP2021524370 A JP 2021524370A JP 2021524370 A JP2021524370 A JP 2021524370A JP 2022512944 A5 JP2022512944 A5 JP 2022512944A5
Authority
JP
Japan
Prior art keywords
cancer
combination according
antibody
acting
long
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021524370A
Other languages
English (en)
Japanese (ja)
Other versions
JP7611136B2 (ja
JP2022512944A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/060609 external-priority patent/WO2020097556A1/en
Publication of JP2022512944A publication Critical patent/JP2022512944A/ja
Publication of JP2022512944A5 publication Critical patent/JP2022512944A5/ja
Priority to JP2024226179A priority Critical patent/JP2025041784A/ja
Application granted granted Critical
Publication of JP7611136B2 publication Critical patent/JP7611136B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021524370A 2018-11-09 2019-11-08 別の薬理学的に活性な薬剤と組み合わせた長時間作用型インターロイキン－１５受容体作動薬 Active JP7611136B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024226179A JP2025041784A (ja) 2018-11-09 2024-12-23 別の薬理学的に活性な薬剤と組み合わせた長時間作用型インターロイキン－１５受容体作動薬

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201862758344P 2018-11-09 2018-11-09
US62/758,344 2018-11-09
US201962789924P 2019-01-08 2019-01-08
US62/789,924 2019-01-08
US201962818003P 2019-03-13 2019-03-13
US62/818,003 2019-03-13
US201962825437P 2019-03-28 2019-03-28
US62/825,437 2019-03-28
US201962843036P 2019-05-03 2019-05-03
US62/843,036 2019-05-03
US201962848372P 2019-05-15 2019-05-15
US62/848,372 2019-05-15
US201962924015P 2019-10-21 2019-10-21
US62/924,015 2019-10-21
PCT/US2019/060609 WO2020097556A1 (en) 2018-11-09 2019-11-08 Long-acting interleukin-15 receptor agonist in combination with another pharmacologically active agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024226179A Division JP2025041784A (ja) 2018-11-09 2024-12-23 別の薬理学的に活性な薬剤と組み合わせた長時間作用型インターロイキン－１５受容体作動薬

Publications (3)

Publication Number Publication Date
JP2022512944A JP2022512944A (ja) 2022-02-07
JP2022512944A5 true JP2022512944A5 (cg-RX-API-DMAC10.html) 2022-11-08
JP7611136B2 JP7611136B2 (ja) 2025-01-09

Family

ID=70611137

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021524370A Active JP7611136B2 (ja) 2018-11-09 2019-11-08 別の薬理学的に活性な薬剤と組み合わせた長時間作用型インターロイキン－１５受容体作動薬
JP2024226179A Pending JP2025041784A (ja) 2018-11-09 2024-12-23 別の薬理学的に活性な薬剤と組み合わせた長時間作用型インターロイキン－１５受容体作動薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024226179A Pending JP2025041784A (ja) 2018-11-09 2024-12-23 別の薬理学的に活性な薬剤と組み合わせた長時間作用型インターロイキン－１５受容体作動薬

Country Status (10)

Country Link
US (1) US20210393742A1 (cg-RX-API-DMAC10.html)
EP (1) EP3876974A4 (cg-RX-API-DMAC10.html)
JP (2) JP7611136B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210090203A (cg-RX-API-DMAC10.html)
CN (1) CN112955168A (cg-RX-API-DMAC10.html)
AU (1) AU2019376164B2 (cg-RX-API-DMAC10.html)
CA (1) CA3119049A1 (cg-RX-API-DMAC10.html)
IL (1) IL283020A (cg-RX-API-DMAC10.html)
MX (1) MX2021005485A (cg-RX-API-DMAC10.html)
WO (1) WO2020097556A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201900022590A1 (it) 2019-11-29 2021-05-29 Italtractor Sistema di monitoraggio per sottocarro cingolato
CN117321087A (zh) 2021-03-26 2023-12-29 先天制药公司 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质
WO2022256534A1 (en) * 2021-06-03 2022-12-08 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
CN117616050A (zh) 2021-06-09 2024-02-27 先天制药公司 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
EP2388266B1 (en) * 2007-05-11 2014-04-23 Altor BioScience Corporation Fusion molecules and IL-15 variants
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
WO2012162547A2 (en) 2011-05-25 2012-11-29 Amylin Pharmaceuticals, Inc. Long duration dual hormone conjugates
US20130302274A1 (en) * 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
MA39711A (fr) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
CA2953816C (en) * 2014-06-30 2022-03-15 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
EP3206713A4 (en) * 2014-10-14 2018-06-27 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
MX2018007304A (es) * 2015-12-21 2019-03-14 Armo Biosciences Inc Composiciones de interleucina-15 y sus usos.
KR20250057110A (ko) * 2017-05-15 2025-04-28 넥타르 테라퓨틱스 지속 작용성 인터류킨-15 수용체 효현제 및 관련 면역요법 조성물 및 방법

Similar Documents

Publication Publication Date Title
US20240009196A1 (en) Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
TWI786044B (zh) 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
JP7126941B2 (ja) がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ
CN105636986B (zh) 包含vegf拮抗剂和抗-ctla-4抗体的组合的方法和组合物
US20200352975A1 (en) Combinations and uses thereof
US20220324965A1 (en) Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
US20200353077A1 (en) Combinations and uses thereof
KR20170117113A (ko) 면역 관문 저해제와 조합한 플리나불린의 용도
HK1251152A1 (en) Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
US11224654B2 (en) Combinations and uses thereof
Blaszczak et al. Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma
JP2011074093A (ja) 抗がん剤
AU2012296907A1 (en) Combination therapy with an anti - CD19 antibody and a nitrogen mustard
CA2797182A1 (en) Methods of enhancing antibody-dependent cellular cytotoxicity
KR20240082379A (ko) 암 치료 방법 및 이의 약제학적 조성물
ES2951864T9 (es) Combinación de un anticuerpo biespecífico ERBB-2/ERBB-3 con terapia endocrina para el cáncer de mama
CN110177807B (zh) 使用抗MUC1抗体和ErbB抑制剂的抗癌治疗
JP2024540536A5 (cg-RX-API-DMAC10.html)
WO2016163433A1 (ja) 抗ｆｇｆｒ２抗体と他剤を含む組成物
CN120302979A (zh) 针对CD40和CD137的多特异性抗体与抗PD1 Ab和化学治疗的组合治疗
Revill et al. Catumaxomab
NZ793707A (en) Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
NZ617770B2 (en) Combination therapy with an anti - cd19 antibody and a nitrogen mustard